idarubicin has been researched along with Leukemia, Myeloid in 161 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.62) | 18.7374 |
| 1990's | 60 (37.27) | 18.2507 |
| 2000's | 88 (54.66) | 29.6817 |
| 2010's | 12 (7.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heisel, RW; Lim, SH; Mascara, GP; Oleksiuk, LM; Sutton, RR; Weber, DR; Winger, DG | 1 |
| Chen, Y; Cheng, N; Feng, Y; Lai, W; Liu, J; Zhang, L | 1 |
| Cao, X; Cen, J; Chen, Z; Gu, W; Li, M; Liu, Y; Xiang, L; Xie, X; Zhen, X | 1 |
| Altman, J; Czerniak, C; Greenberg, D; Koslosky, M; Mehta, J; Pantiru, M; Pi, J; Trifilio, S; Zhou, Z | 1 |
| Abraham, R; Barkoh, BA; Luthra, R; Medeiros, LJ; Mehrotra, M; Mishra, BM; Patel, KP; Ravandi, F; Sargent, RL | 1 |
| Braun, JT; Freter, CE; Lionberger, JM; Petruska, PJ; Ramlal, R; Schoen, MW; Woelich, SK | 1 |
| Berlanga, JJ; Besalduch, J; Brunet, S; Bueno, J; Esteve, J; Gallardo, D; Guardia, R; Heras, I; Hoyos, M; Llorente, A; Nomdedeu, J; Pérez-García, A; Ribera, JM; Sierra, J; Tormo, M | 1 |
| Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W | 1 |
| Amadori, S; Baila, L; de Witte, T; Di Raimondo, F; Fazi, P; Ferrara, F; Labar, B; Liso, V; Mandelli, F; Marie, JP; Marmont, F; Meloni, G; Muus, P; Petti, MC; Stasi, R; Suciu, S; Thomas, X; Vignetti, M; Willemze, R; Zittoun, R | 1 |
| Agha, M; Boyiadzis, M; Foon, KA; Luong, TM; McHayleh, W; Natale, J; Raptis, A; Redner, RL; Schlesselman, JJ; Sehgal, R | 1 |
| Dallmann, I; Ganser, A; Morgan, MA; Onono, FO; Reuter, CW; Scherr, M; Spielmann, HP; Subramanian, T; Venturini, L | 1 |
| Bieg, B; Kostrzewa-Nowak, D; Paine, MJ; Tarasiuk, J; Wolf, CR | 1 |
| Chi, M; Estey, E; Lin, A; McQuary, A; Othus, M | 1 |
| Huh, J; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, SH; Kim, YK; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, J; Shin, MG; Sohn, SK; Won, JH | 1 |
| Chernick, M; Hallquist, A; Perree, M; Presant, CA; Raptis, A; Rutledge, J; Strickland, SA; Talbott, MS | 1 |
| Agresta, S; Amrein, PC; Attar, EC; Ballen, KK; Borger, DR; Burke, M; Chen, YB; Edmonds, KM; Emadi, A; Fathi, AT; Foster, J; Hill, C; Iafrate, AJ; Lopez, HU; Matulis, CR; Neuberg, DS; Sadrzadeh, H; Schenkein, DP; Stone, RM; Straley, KS; Yen, KE | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D | 1 |
| Barbui, T; Bassan, R; Buelli, M; Chiodini, B; Giussani, U; Lerede, T; Oldani, E; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Andreu, R; Benlloch, L; Cervera, J; de la Rubia, J; García, I; Jarque, I; Jiménez, C; Martín, G; Martínez, J; Mollá, S; Moscardó, F; Regadera, A; Sanz, G; Sanz, M | 1 |
| Abbott, BL; Andreeff, M; Barnes, Y; Colapietro, AM; Marini, F; Sorrentino, BP | 1 |
| Beelen, D; Flasshove, M; Kasimir-Bauer, S; Noppeney, R; Scheulen, ME; Seeber, S | 1 |
| Grimes, BA; Guzman, ML; Howard, DS; Jordan, CT; Rossi, RM; Swiderski, CF; Szilvassy, SJ | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Estey, EH; Thall, PF | 1 |
| Arber, DA; Dagis, A; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, AP; Niland, JC; O'Donnell, MR; Parker, P; Rodriguez, R; Slovak, ML; Snyder, DS; Somlo, G; Spielberger, RT; Stein, AS; Vora, N; Wang, S | 1 |
| Brunet, S; Bueno, J; Esteve, J; Llorente, A; Oriol, A; Ribera, JM | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Baer, MR; Barcos, M; Blumenson, L; Ferrone, S; Ford, LA; McElwain, BK; Mortazavi, A; Slack, JL; Stewart, CC; Wetzler, M | 1 |
| Pandit, SR; Raheem, MA | 1 |
| Berry, DA; Cortes, JE; Estey, EH; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Thomas, DA; Verstovsek, S; Wathen, JK; Xiao, LC | 1 |
| Amadori, S; Anak, O; Aul, C; Beeldens, F; Belhabri, A; de Witte, T; Ferrant, A; Hess, U; Jehn, U; Labar, B; Mandelli, F; Muus, P; Oosterveld, M; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| Bernabei, P; Biscardi, M; Caporale, R; Ciolli, S; Grossi, A; Leoni, F; Pagliai, G; Santini, V | 1 |
| Burnett, AK; Chopra, R; Clark, RE; Culligan, D; Hunter, A; Kell, WJ; Milligan, DW; Prentice, AG; Rohatiner, A; Yin, JA | 1 |
| Ito, Y; Katagiri, T; Nakajima, A; Ohyashiki, K; Shimamoto, T | 1 |
| Geissler, K; Hauswirth, AW; Knöbl, P; Sperr, WR; Valent, P; Wimazal, F | 1 |
| Amadori, S; Buccisano, F; Coco, FL; Consalvo, MI; Cudillo, L; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Franchi, A; Lo-Coco, F; Maurillo, L; Mazzone, C; Picardi, A; Tamburini, A; Venditti, A | 1 |
| Björkholm, M; Höglund, M; Juliusson, G; Karlsson, K; Löfgren, C; Möllgård, L; Paul, C; Tidefelt, U | 1 |
| Ahlgren, T; Billström, R; Brune, M; Hedenus, M; Höglund, M; Markevärn, B; Nilsson, B; Sallerfors, B; Simonsson, B; Stockelberg, D; Wahlin, A | 1 |
| Hoffbrand, AV; Koh, M; Mehta, A; Potter, M; Prentice, HG; Rankin, P; Virchis, A | 1 |
| Alonzo, TA; Aplenc, R; Arndt, C; Barnard, D; Dinndorf, P; Feig, S; Feusner, J; Gerbing, R; Lange, BJ; Seibel, N; Smith, FO; Weiman, M | 1 |
| Blijlevens, NM; de Pauw, BE; Donnelly, JP; M'Rabet, L; van't Land, B | 1 |
| Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Hoeffken, K; Hoelzer, D; Hofmann, WK; Knuth, A; Koelbel, CB; Kolbe, K; Langer, W; Ottmann, OG; Schmoll, HJ; Westerhausen, M; Wiebe, S; Zander, C | 1 |
| Colburn, DE; Giles, FJ; Oladovich, D; Smith, JA | 1 |
| Arthur, C; Bashford, J; Baxter, H; Bradstock, KF; Brighton, T; Cannell, P; Catalano, J; Dunlop, L; Durrant, S; Eliadis, P; Enno, A; Gill, D; Gillett, A; Joshua, D; Juneja, S; Koutts, J; Leahy, M; Lowenthal, RM; Matthews, JP; Schwarer, AP; Szer, J; Taylor, K; Young, GA | 1 |
| Batlle, M; Besalduch, J; Brunet, S; Bueno, J; Carreras, E; Esteve, J; Feliu, E; Guàrdia, R; Julià, A; Llorente, A; Montserrat, E; Oriol, A; Pedro, C; Ribera, JM; Sánchez, JM; Sierra, J; Tormo, M; Vilà, JM; Vivancos, P | 1 |
| Annunziata, M; Califano, C; D'Arco, AM; Ferrara, F; Mele, G; Palmieri, S; Pocali, B; Viola, A | 1 |
| Brown, CA; Hashem, B; Lane, JE; Lesher, JL; Marzec, T | 1 |
| Addamo, B; Benner, A; Biedermann, HG; del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Glasmacher, A; Götze, K; Griesinger, F; Grimminger, W; Haas, R; Hartmann, F; Hensel, M; Kirchen, H; Koller, E; Kremers, S; Mergenthaler, HG; Pralle, H; Preiss, J; Salwender, H; Schlenk, RF; Schoch, R; Waterhouse, C | 1 |
| Braess, J; Büchner, T; Fiegl, M; Hiddemann, W | 1 |
| Benderra, Z; Chaoui, D; Faussat, AM; Legrand, O; Marie, JP; Perrot, JY; Sayada, L | 1 |
| De Simone, M; Fasanaro, A; Ferrara, F; Mele, G; Palmieri, S; Pocali, B; Sagristani, M; Viola, A | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Armata, J; Balcerska, A; Balwierz, W; Chybicka, A; Dluzniewska, A; Kowalczyk, J; Matysiak, M; Ochocka, M; Radwanska, U; Rokicka-Milewska, R; Sonta-Jakimczyk, D; Wachowiak, J; Wysocki, M | 1 |
| Horácek, JM; Jebavý, L; Malý, J; Praus, R; Pudil, R; Strasová, A; Tichý, M; Zák, P | 1 |
| Avanzini, P; Baccarani, M; Bocchia, M; Bonini, A; Candoni, A; Castelli, M; Damiani, D; de Vivo, A; Fanin, R; Fiacchini, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michielutti, A; Ottaviani, E; Piccaluga, PP; Pricolo, G; Raspadori, D; Rondoni, M; Russo, D; Testoni, N; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C | 1 |
| Apostolidis, I; Arvanitopoulou, E; Asprogeraka, T; Bakiri, M; Giannakoulas, N; Kotsianidis, I; Marinakis, T; Matsouka, P; Pagoni, M; Papaioannou, M; Skandali, A; Spanoudakis, E; Tsatalas, K; Viniou, N; Yataganas, X; Zikos, P | 1 |
| Benner, A; Biedermann, HG; Del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Glasmacher, A; Götze, K; Haase, D; Hartmann, F; Hensel, M; Kirchen, H; Koller, E; Kremers, S; Matzdorff, A; Mergenthaler, HG; Nerl, C; Pralle, H; Salwender, H; Schlenk, RF; Schoch, R | 1 |
| Hanada, R; Horibe, K; Kobayashi, R; Tawa, A; Tsuchida, M; Tsukimoto, I | 1 |
| Belloc, F; Lacombe, F; Pigneux, A; Praloran, V; Tabrizi, R; Vial, JP | 1 |
| Antonioli, E; Baccini, M; Bosi, A; Gianfaldoni, G; Leoni, F; Mannelli, F | 1 |
| Adamo, F; Amadori, S; Beeldens, F; Berneman, Z; de Witte, T; Fazi, P; Fillet, G; Jehn, U; Lefrère, F; Leone, G; Mandelli, F; Marie, JP; Montanaro, M; Muus, P; Nobile, F; Ricciuti, F; Rizzoli, V; Suciu, S; Thomas, X; Willemze, R | 1 |
| Creutzig, U; Dworzak, M; Graf, N; Hermann, J; Lehrnbecher, T; Niemeyer, CM; Reinhardt, D; Reiter, A; Ritter, J; Stary, J; Zimmermann, M | 1 |
| Li, JY; Qian, SX; Qiu, HR; Shen, RL; Wu, YJ; Zhang, JF; Zhang, SJ; Zhou, HF | 1 |
| Baek, JH; Kim, DH; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Sohn, SK; Yang, DH | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Albitar, M; Borthakur, G; Cortes, J; Faderl, S; Ferrajoli, A; Giles, FJ; Kantarjian, H; Kornblau, S; Pierce, S; Ravandi, F; Thomas, D; Verstovsek, S; Wierda, W | 1 |
| Amadori, S; Broccia, G; de Witte, T; Feremans, W; Fillet, G; Jehn, U; Leone, G; Meloni, G; Rio, B; Suciu, S; Thomas, X; Vignetti, M | 1 |
| Bordessoule, D; Bourhis, JH; Castaigne, S; Contentin, N; de Botton, S; de Revel, T; Dombret, H; Fagot, T; Fenaux, P; Gardin, C; Michallet, M; Pautas, C; Preudhomme, C; Raffoux, E; Reman, O; Terre, C; Thomas, X; Turlure, P | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| Albarello, A; Bacigalupo, A; Balleari, E; Balocco, M; Carella, AM; Catania, G; Clavio, M; Gobbi, M; Manna, A; Michelis, G; Miglino, M; Pierri, I; Sessarego, M; Van Lint, MT; Varaldo, R; Vignolo, L | 1 |
| Genev, ED; Grudeva-Popova, JG; Lazarova, A; Mumdjiev, IN; Spasova, MI; Stoyanova, AA | 1 |
| Baer, MR; Bloomfield, CD; Brunetto, VL; Christiansen, NP; Frankel, SR; Herzig, GP; Mrózek, K | 1 |
| Curtis, JE; McCulloch, EA; Minden, MD; Minkin, S | 1 |
| Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F | 1 |
| Archimbaud, E; Muus, P; Willemze, R | 1 |
| Caporale, R; Cervi, L; Ciolli, S; Giuliani, G; Leoni, F; Pascarella, A; Rossi Ferrini, P; Salti, F | 1 |
| Mehta, J; Philpott, N; Powles, R; Treleaven, J | 1 |
| Cianfriglia, M; Eisterer, W; Gotwald, M; Hilbe, W; Hofmann, J; Ludescher, C; Thaler, J; Zabernigg, A | 1 |
| Götzl, M; Gsur, A; Kyrle, PA; Lechner, K; Pirker, R; Zöchbauer, S | 1 |
| al-Sabah, A; Baines, P; Burnett, A; Hoy, T; Limaye, M; Padua, RA; Whittaker, J | 1 |
| Conley, NS; Doughney, KB; Durkin, WJ; Favis, GR; Siddiqui, T; Smith, AE; Weiss, R | 1 |
| Fukushima, T; Kawai, Y; Nakamura, T; Ueda, T; Urasaki, Y; Yoshida, A | 1 |
| Aul, C; Burk, M; Gogolin, F; Heyll, A; Meckenstock, G; Runde, V; Söhngen, D; Winkelmann, M; Wolf, HH; Zahner, J | 1 |
| Belloc, F; Boiron, JM; Cony-Makhoul, P; Dubosc-Marchenay, N; Dumain, P; Fabères, C; Lacombe, F; Marit, G; Montastruc, M; Puntous, M | 1 |
| Boezeman, J; de Witte, T; Haanen, C; Linssen, P; Minderman, H; van der Lely, N; Wessels, J | 1 |
| Perilov, AA; Poddubnaia, IV | 1 |
| Almqvist, A; Hallman, H; Honkanen, T; Järvenpää, E; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Ruutu, T | 1 |
| Annaloro, C; Cofrancesco, E; Cortelezzi, A; Cortellaro, M; Della Volpe, A; Lambertenghi Deliliers, G; Mozzana, R; Oriani, A; Pozzoli, E; Soligo, D | 1 |
| Erskine, JG; Goldstone, AH; Newland, AC; Pearce, RM; Powles, RL; Rassam, SM; Smith, AG; Turker, A | 1 |
| Del Valle, F; Döhner, H; Ehrhardt, R; Fischer, JT; Haas, R; Ho, AD; Huberts, H; Hunstein, W; Kaplan, E; Witt, B | 1 |
| Cerutti, I; Fernández-Barbieri, MA; Gomel, M; Kvicala, R; Matus-Ridley, M; Negri-Aranguren, P; Rosso, A; Sackmann-Muriel, F; Santarelli, MT | 1 |
| Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M | 1 |
| Estey, E; Kuschel, B | 1 |
| Belotti, D; Corneo, G; Maffè, PF; Pogliani, EM; Rivolta, GF | 1 |
| Allford, S; Glynne, P; Hamblin, M; Horton, C; Mackay, H; Mehta, J; Powles, R; Prendiville, J; Saso, R; Singhal, S; Treleaven, J; Zomas, A | 1 |
| Manfroi, S; Ottaviani, E; Pellacani, A; Tosi, P; Tura, S; Visani, G | 1 |
| Cortés, MA; Hermida, G; Iriondo, A; Mozota, ML; Olalla, I; Ortín, M; Richard, C; Zubizarreta, A | 1 |
| Campbell, J; De La Serna, J; Diaz-Mediavilla, J; Francisco Tomás, J; García de Paredes, ML; Grande, C; Solano, C | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Galloway, MJ; Hamilton, PJ; Haynes, A; Iqbal, A; Jackson, GH; Proctor, SJ; Russell, N; Taylor, PR; Turner, G | 1 |
| Heitjan, DF | 1 |
| Allen, PD; Kelsey, SM; Ketley, NJ; Newland, AC | 2 |
| Abgrall, JF; Audhuy, B; Briere, J; Cahn, JY; Caillot, D; Casassus, P; Delain, M; Desablens, B; Francois, S; Guilhot, F; Guyotat, D; Harousseau, JL; Herve, P; Hurteloup, P; Lamy, T; Lioure, B; Milpied, N; Pignon, B; Tellier, Z; Witz, F | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Bartolucci, A; Berman, E; Vélez-Gárcia, E; Vogler, R; Whaley, FS; Wiernik, P | 1 |
| Cullis, JO; Czepulkowski, B; Gover, PA; Grace, R; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE; Rassam, SM; Samaratunga, IR | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Borleri, G; Buelli, M; Lerede, T; Rambaldi, A | 1 |
| de Witte, T; Jerjis, S; Muus, P; Roovers, E; Schaap, N | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Brusamolino, E; Canevari, A; Castagnola, C; Castelli, G; Lazzarino, M; Pagnucco, G | 1 |
| Bow, EJ; Gallant, G; Rubinger, M; Schacter, BA; Shore, TB; Williams, GJ; Woloschuk, D | 1 |
| Boiron, JM; Cardinaud, JP; Gbikpi-Benissan, G; Gruson, D; Guisset, O; Hilbert, G; Pigneux, A; Reiffers, J; Texier, J; Vargas, F | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Kirch, C; Schröder, JK; Schütte, J; Seeber, S | 1 |
| Engelhardt, R; Grotz, W; Lübbert, M; Rump, LC; Würthner, J | 1 |
| Goa, KL; Whittington, R | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, EH; Freireich, E; Kantarjian, H; Keating, MJ; Pierce, S; Thall, PF | 1 |
| Amadori, S; Archimbaud, E; Belhabri, A; De Cataldo, F; Fillet, G; Jehn, U; Martin, C; Peaud, PY; Thomas, X; Willemze, R | 1 |
| Cavaliere, M; Clavio, M; Gobbi, M; Miglino, M; Pierri, I; Pietrasanta, D | 1 |
| Kneisl, JS; Lipford, EH; Woodard, WL | 1 |
| Gherlinzoni, F; Isidori, A; Lemoli, R; Leopardi, G; Martinelli, G; Motta, M; Pastano, R; Piccaluga, P; Ricci, P; Rizzi, S; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Bishop, JF; Bradstock, KF; Cobcroft, R; Eliadis, P; Enno, A; Gill, D; Herrmann, RP; Juneja, S; Lowenthal, RM; Manoharan, A; Matthews, JP; Page, FJ; Rooney, KF; Rosenfeld, D; Seldon, M; Taylor, KM; Wolf, MM; Young, GA | 1 |
| Kulkarni, S; Mehta, J; Min, T; Powles, R; Saso, R; Singhal, S; Swansbury, GJ; Treleaven, J | 1 |
| Bauduer, F; Bouabdallah, R; Castaigne, S; Chaïbi, P; Coso, D; Fenaux, P; Harousseau, JL; Lefrère, F; Robert, J; Rose, C; Varet, B; Vernant, JP; Zini, JM | 1 |
| Dias Wickramanayake, P; Diehl, V; Franklin, J; Glasmacher, A; Neufang, A; Scheid, C; Schulz, A; Staib, P; Steinmetz, HT; Tesch, H | 1 |
| Belaud-Rotureau, MA; Belloc, F; Bernard, P; Boisseau, MR; Dumain, P; Durrieu, F; Lacombe, F; Reiffers, J | 1 |
| Mandelli, F; Montefusco, E | 1 |
| Bergmann, L; Brack, N; Brockhaus, W; Fischer, JT; Fuhr, HG; Ganser, A; Heil, G; Hoelzer, D; Höffken, K; Hofmann, W; Ittel, TH; Knuth, P; Kolbe, K; Langer, W; Seipelt, G | 1 |
| Döhner, H; Döhner, K; Schlenk, RF; van der Reijden, BA | 1 |
| Agape, P; Belaud-Rotureau, MA; Belloc, F; Durrieu, F; Fitoussi, O; Labroille, G; Lacombe, F; Marit, G; Reiffers, J | 1 |
| Clowes, C; Duarte, R; Pu, QQ; Wang, X | 1 |
| Arima, N; Fukushima, T; Kanamaru, A; Kishimoto, Y; Kusumoto, GS; Motoji, T; Ohno, R; Okamoto, T; Shimazaki, C; Takahashi, M; Takemoto, Y; Takeshita, A; Tsukuda, K; Uike, N; Yorimitsu, S | 1 |
| Beelen, DW; Brittinger, G; Flasshove, M; Kemmeries, G; Meusers, P; Noppeney, R; Roggenbuck, U; Scheulen, ME; Schütte, J; Seeber, S; Sohrab, S | 1 |
| Appelbaum, FR; Cassileth, PA; Forman, SJ; Harrington, DH; Head, DR; Kopecky, KJ; Mohamed, A; Paietta, E; Rowe, JM; Slovak, ML; Theil, KS; Willman, CL | 1 |
| al-Ramadi, B; Ellis, M; Gorka, W; Shamoon, A; Zwaan, F | 1 |
| Cheng, G; Chik, KW; Chui, CH; Lau, FY; Li, CK; Tsang, KS; Wong, R | 1 |
| de Witte, T; Linssen, P; Masereeuw, R; Muus, P; Raymakers, R; Smeets, M; Vierwinden, G | 1 |
| Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Bernasconi, P; Boni, M; Castoldi, GL; Ciolli, S; Clavio, M; Cox, MC; Cuneo, A; Del Poeta, G; Dini, D; Falzetti, D; Fanin, R; Gobbi, M; Isidori, A; Leoni, F; Liso, V; Malagola, M; Mandelli, F; Martinelli, G; Mecucci, C; Petti, MC; Piccaluga, PP; Rondelli, R; Russo, D; Sessarego, M; Specchia, G; Testoni, N; Torelli, G; Tura, S; Visani, G | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Baccarani, M; Bertone, A; Bucalossi, A; De Vivo, A; Gobbi, M; Lauria, F; Marin, L; Mazza, P; Michelutti, A; Michieli, M; Pierri, I; Pricolo, G; Raspadori, D; Russo, D; Zaccaria, A; Zuffa, E | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Arthur, C; Bashford, J; Baxter, H; Bradstock, K; Brighton, T; Cannell, P; Dunlop, L; Durrant, S; Eliadis, P; Enno, A; Gill, D; Gillett, A; Gottlieb, D; Januszewicz, H; Joshua, D; Leahy, M; Lowenthal, R; Matthews, J; Schwarer, A; Taylor, K; Young, G | 1 |
| Hills, RK; Wheatley, K | 1 |
| Faber, E; Hlusí, A; Hubácek, J; Indrák, K; Jarosová, M; Jebavý, L; Kmonícek, M; Knotková, R; Krahulová, M; Malý, J; Mayer, J; Penka, M; Szotkowski, T; Voglová, J; Zapletalová, J | 1 |
| Craddock, C; Garg, M; Lawler, M; Pawson, R; Potter, MN; Prentice, HG; Rassam, S; Rezvani, K; Theocharous, P; Yin, JA | 1 |
| Anagnostopoulos, N; Androutsos, G; Galanopoulos, A; Kalmantis, T; Meletis, J; Paterakis, G; Rombos, Y; Sagriotis, A; Symeonidis, A; Tiniakou, M; Tsimberidou, AM; Yataganas, X; Zoumbos, N | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
| Annunziata, M; Copia, C; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pollio, F; Russo, C; Schiavone, EM; Viola, A | 1 |
| Anglaret, B; Archimbaud, E; Belhabri, A; Chelghoum, Y; Dhedin, N; Dombret, H; Fière, D; Michallet, M; Reman, O; Thomas, X; Vekhoff, A; Wattel, E | 1 |
| Beksac, M; Dalva, K; Hayran, M; Ilhan, O; Koc, H; Konuk, N; Ozcan, M; Sertkaya, D; Topcuoglu, P; Ustün, C | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; Pierce, SA; Thall, PF; Thomas, DA; Wang, XM | 1 |
| Huguet, F; Hurteloup, P; Michallet, M; Reiffers, J; Stoppa, AM | 1 |
| Abgrall, JF; Desablens, B; Dufour, P; Guyotat, D; Harousseau, JL; Herve, P; Ifrah, N; Milpied, N; Pignon, B; Solary, E | 1 |
| Ames, MM; Kuffel, MJ; Reid, JM | 1 |
| Wiernik, PH | 1 |
| Battista, R; D'Emilio, A; Dini, E; Pacciarini, MA; Vespignani, M | 1 |
8 review(s) available for idarubicin and Leukemia, Myeloid
| Article | Year |
|---|---|
Treatment concepts for elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Etoposide; Follow-Up Studies; Forecasting; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Palliative Care; Patient Selection; Randomized Controlled Trials as Topic; Thioguanine; Time Factors | 2003 |
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis | 1998 |
Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.
Topics: Adult; Aged; Bone Marrow Transplantation; Cost-Benefit Analysis; Cytarabine; Drug Therapy, Combination; Drug Tolerance; Economics, Pharmaceutical; Formularies as Topic; Health Care Costs; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Treatment Outcome | 1993 |
[Treatment of acute and chronic leukemias].
Topics: Acute Disease; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Daunorubicin; Humans; Idarubicin; Karyotyping; Leukemia; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Transplantation, Autologous; Transplantation, Homologous | 1999 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Splenomegaly; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
70 trial(s) available for idarubicin and Leukemia, Myeloid
| Article | Year |
|---|---|
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Topics: 3' Untranslated Regions; Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; CTLA-4 Antigen; Cytarabine; Disease-Free Survival; Etoposide; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Recurrence; Remission Induction; Young Adult | 2009 |
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Oligonucleotides; Peripheral Nervous System Diseases; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2009 |
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Apoptosis; Disease-Free Survival; Female; Humans; Idarubicin; Kinetics; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Prognosis; Remission Induction; Treatment Outcome; Tumor Cells, Cultured; Young Adult | 2013 |
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 2002 |
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infections; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytosine; Dioxolanes; Female; Humans; Idarubicin; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival; Treatment Outcome | 2003 |
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aminoglycosides; Amsacrine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cohort Studies; Cytarabine; Doxorubicin; Etoposide; Feasibility Studies; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Pilot Projects; Remission Induction; Thioguanine; Vidarabine | 2003 |
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Predictive Value of Tests; Probability; Recurrence; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2003 |
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Rate | 2003 |
More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Caspase 14; Caspases; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Transplantation, Autologous | 2003 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Thioguanine; Treatment Outcome | 2004 |
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2004 |
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Treatment Outcome | 2005 |
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Remission Induction; Transplantation, Autologous | 2004 |
Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
Topics: Acute Disease; Administration, Oral; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Secondary Prevention; Survival Rate; Transplantation Conditioning | 2004 |
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous; Tretinoin | 2004 |
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
Topics: Acute Disease; Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Risk; Survival Analysis | 2005 |
High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2005 |
Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Bone Marrow Transplantation; Cause of Death; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Poland; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2005 |
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Greece; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Societies, Medical; Survival Analysis; Treatment Outcome | 2006 |
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.
Topics: Acute Disease; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2006 |
Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Marrow Transplantation; Caspases; Cell Count; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Common Antigens; Leukocyte Count; Lymphocytes; Male; Middle Aged; Prognosis; Remission Induction | 2006 |
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Intravenous; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pancytopenia; Patient Compliance; Risk Factors | 2006 |
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cranial Irradiation; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid; Male; Mitoxantrone; Neutropenia; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Analysis | 2007 |
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Blood Transfusion; Daunorubicin; Disease-Free Survival; Female; Hospitalization; Humans; Idarubicin; Leukemia, Myeloid; Male; Remission Induction; Survival Rate | 2007 |
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Vidarabine | 2007 |
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Diseases; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms; Prospective Studies; Radiotherapy; Remission Induction; Salvage Therapy; Treatment Outcome | 1994 |
MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cytarabine; Daunorubicin; Drug Resistance; Female; Follow-Up Studies; Gene Expression; Humans; Idarubicin; Leukemia, Myeloid; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Remission Induction; RNA, Neoplasm; Survival Rate; Treatment Outcome | 1993 |
Comparison of survival. Chemotherapeutically treated and untreated older patient with acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Sex Factors; Survival Rate; Thioguanine | 1994 |
Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Survival Analysis | 1994 |
Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid; Male; Remission Induction; Thioguanine | 1994 |
Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Survival Analysis | 1993 |
Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Analysis | 1993 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Acute Disease; Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged | 1996 |
Anthracycline drugs and MDR expression in human leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction | 1996 |
Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Agranulocytosis; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Nausea; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Prognosis; Remission Induction | 1997 |
Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Daunorubicin; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Survival Analysis; Treatment Outcome | 1997 |
A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Over Studies; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence | 1998 |
Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 1998 |
Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gene Rearrangement; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 1998 |
Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Tolerance; Etoposide; Female; Humans; Idarubicin; Intestinal Mucosa; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome; Xylose | 1998 |
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Survival Rate; Time Factors; Tretinoin; Vidarabine | 1999 |
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with
Topics: Acute Disease; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Double-Blind Method; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pilot Projects; Transplantation, Autologous | 1999 |
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 1999 |
The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Middle Aged; Multivariate Analysis; Remission Induction; Treatment Outcome | 1999 |
A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome | 1999 |
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Fever of Unknown Origin; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Recurrence; Vidarabine | 1999 |
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Immunotherapy; Interleukin-2; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate | 2000 |
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Topics: Acute Disease; Adolescent; Adult; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Remission Induction; Risk; Survival Analysis; Translocation, Genetic; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2000 |
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia; Pilot Projects; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Topics: Acute Disease; Adjuvants, Immunologic; Adult; Cost-Benefit Analysis; Cytarabine; Female; Glycosylation; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Survival Rate | 2001 |
[Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].
Topics: Acute Disease; Aged; Antineoplastic Agents; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prospective Studies; Remission Induction; Survival Rate | 2001 |
High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Feasibility Studies; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Stroke Volume; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2001 |
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Therapeutic Equivalency; Treatment Outcome; Tretinoin | 2002 |
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Cytarabine; Drug Therapy, Combination; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Infusions, Parenteral; Interleukin-11; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Therapeutic Equivalency | 2002 |
Intensive induction chemotherapy in elderly patients. The BGMT Group.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged | 1992 |
Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; France; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Autologous | 1992 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
85 other study(ies) available for idarubicin and Leukemia, Myeloid
| Article | Year |
|---|---|
Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cephalosporins; Cytarabine; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Vancomycin; Vancomycin-Resistant Enterococci; Young Adult | 2017 |
A Case of Granulocytic Sarcoma of the Lung in Acute Myeloid Leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid | 2019 |
The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; Nucleophosmin; Peripheral Blood Stem Cell Transplantation; Prognosis; Real-Time Polymerase Chain Reaction; RNA, Neoplasm; Survival Analysis; Trans-Activators; Transplantation, Autologous; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine; Young Adult | 2013 |
Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Young Adult | 2013 |
Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Comparative Genomic Hybridization; Cytarabine; DNA Copy Number Variations; Drug Administration Schedule; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Remission Induction | 2014 |
Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Exanthema; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Mucositis; Neutropenia; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.
Topics: Anthracyclines; Antigens, Neoplasm; Apoptosis; Benzodiazepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dimethylallyltranstransferase; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Synergism; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Imidazoles; Leukemia, Myeloid; MAP Kinase Signaling System; Poly-ADP-Ribose Binding Proteins; Protein Prenylation | 2012 |
Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leuka
Topics: Anthraquinones; Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; Heterocyclic Compounds, 4 or More Rings; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; NADPH-Ferrihemoprotein Reductase | 2012 |
Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fever; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Neutropenia; Obesity; Outcome Assessment, Health Care; Prognosis; Remission Induction; Young Adult | 2013 |
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Genome-Wide Association Study; Humans; Idarubicin; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Remission Induction; Translocation, Genetic; Young Adult | 2012 |
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; DNA Mutational Analysis; Female; Glutarates; Granulocyte Precursor Cells; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prospective Studies; Time Factors | 2012 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Headache; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplastic Stem Cells; Patient Compliance; Pilot Projects; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Failure; Tretinoin | 2002 |
Low levels of ABCG2 expression in adult AML blast samples.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood Cells; Bone Marrow Cells; Drug Resistance, Neoplasm; Female; Fetal Blood; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Idarubicin; Infant, Newborn; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; RNA, Messenger; RNA, Neoplasm; Topotecan | 2002 |
Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression; Genes, bcl-2; Genes, MDR; Genes, p53; Heat-Shock Proteins; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Preferential induction of apoptosis for primary human leukemic stem cells.
Topics: Acute Disease; Alleles; Animals; Antibiotics, Antineoplastic; Apoptosis; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Gene Expression Regulation, Leukemic; Graft Survival; Hematopoietic Stem Cells; Humans; I-kappa B Proteins; Idarubicin; Leukemia, Myeloid; Leukocytes; Leupeptins; Mice; Mice, Inbred NOD; Mice, SCID; Multienzyme Complexes; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; NF-kappa B; Proteasome Endopeptidase Complex; Recombinant Fusion Proteins; Tumor Suppressor Protein p53 | 2002 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
New designs for phase 2 clinical trials.
Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome | 2003 |
Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid; Male; Middle Aged; Stem Cell Transplantation | 2003 |
Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Survival Analysis; Treatment Outcome | 2003 |
HLA-DR antigen-negative acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; HLA-DR Antigens; Humans; Idarubicin; Immunophenotyping; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prospective Studies; Recurrence; Treatment Outcome | 2003 |
Mucormycosis in acute myeloid leukaemia.
Topics: Acute Disease; Amphotericin B; Antifungal Agents; Combined Modality Therapy; Cytarabine; Frozen Sections; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Mucormycosis; Thoracic Wall | 2003 |
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIM
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Idarubicin; Leukemia, Myeloid; Living Donors; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.
Topics: Acute Disease; Adult; Aged; Annexin A5; Anthracyclines; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Daunorubicin; Female; Humans; Idarubicin; K562 Cells; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Middle Aged; Propidium; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
Myeloid/natural killer cell precursor acute leukemia accompanied by homozygous protein C deficiency.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antineoplastic; Cytarabine; Heparin, Low-Molecular-Weight; Homozygote; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Male; Myeloid Cells; Neoplastic Stem Cells; Pedigree; Protein C Deficiency | 2003 |
Measuring mucosal damage induced by cytotoxic therapy.
Topics: 3-O-Methylglucose; Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Female; Gastric Mucosa; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Intestinal Mucosa; Lactulose; Leukemia, Myeloid; Male; Middle Aged; Mouth Mucosa; Myelodysplastic Syndromes; Permeability; Rhamnose; Stomatitis; Transplantation Conditioning; Whole-Body Irradiation; Xylose | 2004 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.
Topics: Acute Disease; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Caspofungin; Cytarabine; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Interactions; Echinocandins; Humans; Idarubicin; Itraconazole; Leukemia, Myeloid; Lipopeptides; Mycoses; Peptides; Peptides, Cyclic; Substrate Specificity | 2004 |
Pressure-induced bullae and sweat gland necrosis following chemotherapy induction.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blister; Cytarabine; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Idarubicin; Leukemia, Myeloid; Male; Necrosis; Remission Induction; Sweat Gland Diseases; Sweat Glands | 2004 |
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Proliferation; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Rate | 2004 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Creatine Kinase, MB Form; Cytarabine; Echocardiography; Female; Heart Diseases; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Troponin T | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin | 2005 |
Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Central Nervous System; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gingiva; Humans; Hydrocortisone; Idarubicin; Infant; Infant, Newborn; Japan; Kaplan-Meier Estimate; Leukemia, Myeloid; Leukemic Infiltration; Male; Methotrexate; Orbit; Prognosis; Remission Induction; Sarcoma, Myeloid; Skin; Testis | 2007 |
Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction | 2006 |
[Bulky lymphadenopathy in acute myeloid leukemia with inv (16) (p13q22): a case report].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Lymphatic Diseases; Male; Neoplasm, Residual; Prognosis | 2006 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Epidemiologic Methods; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Severity of Illness Index; Treatment Outcome | 2007 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
Pseudomembranous necrotizing tracheobronchitis caused by Aspergillus spp--contribution of one case with acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillus; Bronchitis; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Necrosis; Opportunistic Infections; Radiography, Thoracic; Tracheitis | 2006 |
High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 1993 |
Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors.
Topics: Aged; Aged, 80 and over; Blood Cells; Bone Marrow Cells; Cells, Cultured; Culture Techniques; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Recombinant Proteins; Tumor Cells, Cultured | 1995 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Blood Cell Count; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Gene Expression; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 1995 |
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1993 |
Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Rhodamine 123; Rhodamines; Survival Analysis | 1995 |
In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Survival; Cells, Cultured; Cyclosporine; Daunorubicin; Drug Resistance; Drug Resistance, Multiple; Female; Fluorescent Antibody Technique; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Reference Values | 1994 |
Influence of idarubicinol on the antileukemic effect of idarubicin.
Topics: Daunorubicin; DNA; DNA Damage; Humans; Idarubicin; In Vitro Techniques; Leukemia, Myeloid; Nucleic Acid Synthesis Inhibitors; Tumor Cells, Cultured | 1994 |
Daunorubicin (DNR) accumulation in fresh leukemic cells: correlation with clinical and biological features.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Stimulation, Chemical; Treatment Failure; Verapamil | 1994 |
Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
Topics: Acute Disease; Antineoplastic Agents; Cell Division; Daunorubicin; Doxorubicin; Granulocytes; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myeloid; Macrophages; Tumor Stem Cell Assay | 1994 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; Prognosis; Remission Induction; Time Factors | 1993 |
Idarubicin in the therapy of acute myeloid leukemia: final analysis in 57 previously untreated patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis | 1993 |
Idarubicin for remission induction of acute myeloid leukemia: United Kingdom multicenter experience.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis | 1993 |
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Central Nervous System Neoplasms; Chromosomes, Human, Pair 8; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Neoplasms; Trisomy; Vidarabine | 1995 |
Retinoids increase idarubicin cytotoxicity in human myeloid leukemia cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid; Tretinoin; Tumor Cells, Cultured | 1996 |
Autologous peripheral blood stem cell transplantation in a patient with previous invasive middle ear mucormycosis.
Topics: Acute Disease; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Facial Paralysis; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mastoid; Middle Aged; Mitoxantrone; Mucormycosis; Myringoplasty; Neutropenia; Otitis Media, Suppurative; Remission Induction; Transplantation Conditioning; Transplantation, Autologous | 1996 |
The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy.
Topics: Acute Disease; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Survival Analysis | 1997 |
Bayesian interim analysis of phase II cancer clinical trials.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Models, Statistical; Research Design; Vidarabine | 1997 |
Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor.
Topics: Acute Disease; Antibiotics, Antineoplastic; Apoptosis; Calcitriol; Cell Cycle; Cell Differentiation; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid; Proto-Oncogene Proteins c-bcl-2; Tretinoin; Tumor Cells, Cultured | 1997 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count; Survival Rate; Treatment Outcome; Vidarabine | 1997 |
Severe infection caused by Stomatococcus mucilaginosus in a neutropenic patient: case report and review of the literature.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Leukemia, Myeloid; Micrococcaceae; Mouth; Neutropenia; Opportunistic Infections; Pneumonia, Bacterial; Sepsis | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blotting, Southern; Cytarabine; Cytidine Deaminase; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mutation; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 1998 |
Management of acute myeloid leukaemia following myelodysplastic syndrome in a kidney graft recipient.
Topics: Acute Disease; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cytarabine; Etoposide; Female; Humans; Idarubicin; Imipenem; Kidney Transplantation; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Thienamycins | 1999 |
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged | 1999 |
Isolated granulocytic sarcoma of the humerus.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Cytarabine; Diagnosis, Differential; Fatal Outcome; Humans; Humerus; Idarubicin; Leukemia, Myeloid; Magnetic Resonance Imaging; Male; Pain; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 1999 |
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Transplantation; Clinical Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Evaluation Studies as Topic; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome | 1999 |
Synthesis of Bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic cell lines.
Topics: Antibiotics, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Cell Division; Ceramides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation; HL-60 Cells; Humans; Idarubicin; K562 Cells; Leukemia, Myeloid; Phenotype; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; U937 Cells | 1999 |
Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints.
Topics: Acute Disease; Apoptosis; Calcitriol; Cell Cycle; Cell Differentiation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G1 Phase; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid; Neoplastic Stem Cells; Resting Phase, Cell Cycle; Tretinoin; U937 Cells; Vinblastine | 2000 |
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; DNA-Binding Proteins; Etoposide; Gene Deletion; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Mitoxantrone; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Prognosis; Prospective Studies; Recurrence; Remission Induction | 2000 |
Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Caspase 3; Caspases; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; fas Receptor; Female; Flow Cytometry; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Peptide Hydrolases; Prognosis; Remission Induction; Signal Transduction; Survival Analysis; Treatment Outcome | 2000 |
Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Intercellular Adhesion Molecule-1; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Neutrophils; Recombinant Proteins; Solubility | 2000 |
Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Humans; Idarubicin; Japan; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate | 2000 |
Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Rate | 2000 |
Severe hepatic injury associated with lipid formulations of amphotericin B.
Topics: Adolescent; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Liver; Liver Diseases | 2001 |
Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.
Topics: Acute Disease; Adult; Blood Transfusion; Cytarabine; Fatal Outcome; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; HLA Antigens; Homozygote; Humans; Idarubicin; Leukemia, Myeloid; Male | 2001 |
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Daunorubicin; Female; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Prospective Studies; Recurrence | 2001 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study.
Topics: Acute Disease; Antineoplastic Agents; Bias; Clinical Trials as Topic; Data Interpretation, Statistical; Doxorubicin; Humans; Idarubicin; Leukemia, Myeloid; Odds Ratio | 2001 |
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Filgrastim; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Reoperation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Calcium Channel Blockers; Carbocyanines; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Genistein; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Probenecid; Prognosis; Prospective Studies; Rhodamine 123; Survival Analysis; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Verapamil | 2002 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |
In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Cytarabine; Drug Resistance, Multiple; Etoposide; Female; Fluorescent Dyes; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Rhodamine 123; Treatment Outcome; Tretinoin | 2002 |
Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Topics: Antibiotics, Antineoplastic; Cell Division; Daunorubicin; DNA Damage; DNA, Neoplasm; Doxorubicin; Epirubicin; Glioma; Humans; Idarubicin; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1992 |
Preliminary observations on intravenous idarubicin (4-demethoxydaunorubicin) in the chronic and accelerated phase of chronic myelogenous leukemia.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Platelet Count | 1986 |